Today, the American Gastroenterological Association (AGA) published new COVID-19 recommendations in Gastroenterology, the official journal of the AGA: AGA Institute Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic.
Patients with extreme obesity are prone to unconscious food impulses and cravings that may make it challenging for them to maintain weight loss after bariatric surgery, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.
Researchers have found that a commonly used drug made from secondary bile acids can affect the life cycle of Clostridioides difficile (C. diff) in vitro and reduce the inflammatory response to C. diff in mice.
For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Obese patients may lose more weight if they undergo bariatric surgery before they develop diabetes, suggests a study accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting. The research will be published in a special supplemental issue of the Journal of the Endocrine Society.
Patients with poorly controlled type 2 diabetes who underwent a novel, minimally invasive, endoscopic procedure called Revita® duodenal mucosal resurfacing (DMR) had significantly improved blood glucose (sugar) levels, liver insulin sensitivity, and other metabolic measures three months later, according to new data from the REVITA-2 study. These results, from a mixed meal tolerance test, have helped researchers verify the insulin sensitizing mechanism by which hydrothermal ablation of the duodenum improves blood sugar in patients with type 2 diabetes.
Scientists have identified a specific type of sensory nerve ending in the gut and how these communicate pain or discomfort to the brain, paving the way for targeted treatments for common conditions like ulcerative colitis, irritable bowel syndrome or chronic constipation. While understanding of the gut's neurosensory abilities has grown rapidly, two great mysteries have been where and how different types of sensory nerve endings in the gut lie.
In a series of four studies published today in Gastroenterology, a journal of the American Gastroenterological Association, Mount Sinai inflammatory bowel disease (IBD) researchers, describe the identification of predictive tools and a new understanding of environmental factors that trigger IBD.
Studying mice and fruitflies, researchers found that the enzyme intestinal alkaline phosphotase helped prevent intestinal permeability and gut-derived systemic inflammation, resulting in less frailty and extended life span.
A paper published today in Clinical Gastroenterology and Hepatology by clinicians at Icahn School of Medicine at Mount Sinai outlines key information gastroenterologists and patients with chronic digestive conditions need to know about COVID-19, or coronavirus.